Clinical Trial Update: Safety, Tolerability and Pharmacokinetics Study of LY03005 [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of LY03005 in adults with Major depressive disorder has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• LY03005 (LY03005)

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Major Depressive Disorder | Phase 1 | Status: COMPLETED